B-intervention	0	7	Ovarian
I-intervention	8	16	ablation
I-intervention	17	19	or
I-intervention	20	31	suppression
O	32	34	in
O	35	48	premenopausal
O	49	54	early
O	55	61	breast
O	62	68	cancer
O	68	69	:
O	70	77	results
O	78	82	from
O	83	86	the
O	87	100	international
O	101	109	adjuvant
O	110	116	breast
O	117	123	cancer
O	124	131	ovarian
O	132	140	ablation
O	141	143	or
O	144	155	suppression
O	156	166	randomized
O	167	172	trial
O	172	173	.

O	174	185	Substantial
O	186	194	survival
O	195	203	benefits
O	204	209	exist
O	210	213	for
O	214	222	patients
O	223	227	with
O	228	233	early
O	233	234	-
O	234	239	stage
O	240	246	breast
O	247	253	cancer
O	254	257	who
O	258	265	undergo
O	266	275	treatment
O	276	280	with
O	281	287	single
O	287	288	-
O	288	296	modality
O	297	306	tamoxifen
O	306	307	,
O	308	315	ovarian
O	316	324	ablation
O	325	327	or
O	328	339	suppression
O	339	340	,
O	341	343	or
O	344	356	chemotherapy
O	356	357	.

O	358	360	To
O	361	370	determine
O	371	378	whether
O	379	389	additional
O	390	398	benefits
O	399	404	exist
O	405	409	with
O	410	418	combined
O	419	428	treatment
O	428	429	,
O	430	433	the
O	434	442	Adjuvant
O	443	449	Breast
O	450	456	Cancer
O	457	458	(
O	458	461	ABC
O	461	462	)
O	463	469	Trials
O	470	474	were
O	475	485	undertaken
O	485	486	.

O	487	490	The
O	491	494	ABC
O	495	502	Ovarian
O	503	511	Ablation
O	512	514	or
O	515	526	Suppression
O	527	532	Trial
O	533	541	randomly
O	542	550	assigned
B-eligibility	551	554	pre
I-eligibility	554	555	-
I-eligibility	556	559	and
I-eligibility	560	574	perimenopausal
I-eligibility	575	583	patients
I-eligibility	584	588	with
I-eligibility	589	594	early
I-eligibility	594	595	-
I-eligibility	595	600	stage
I-eligibility	601	607	breast
I-eligibility	608	614	cancer
I-eligibility	615	618	who
I-eligibility	619	623	were
I-eligibility	624	633	receiving
I-eligibility	634	643	prolonged
I-eligibility	644	645	(
I-eligibility	645	646	5
I-eligibility	647	652	years
I-eligibility	652	653	)
I-eligibility	654	663	tamoxifen
I-eligibility	664	673	treatment
I-eligibility	674	678	with
I-eligibility	679	681	or
I-eligibility	682	689	without
I-eligibility	690	702	chemotherapy
O	703	705	to
O	706	713	ovarian
O	714	722	ablation
O	723	725	or
O	726	737	suppression
O	738	739	(
O	739	741	by
O	742	754	oophorectomy
O	754	755	,
O	756	763	ovarian
O	764	775	irradiation
O	775	776	,
O	777	779	or
O	780	789	treatment
O	790	794	with
O	795	806	luteinizing
O	807	814	hormone
O	814	815	-
O	815	824	releasing
O	825	832	hormone
O	833	840	agonist
O	840	841	)
O	842	848	versus
B-control	849	851	no
I-control	852	859	ovarian
I-control	860	868	ablation
I-control	869	871	or
I-control	872	883	suppression
O	883	884	.

O	885	890	Trial
O	891	900	endpoints
O	901	909	included
B-outcome-Measure	910	917	relapse
I-outcome-Measure	917	918	-
I-outcome-Measure	918	922	free
O	923	926	and
B-outcome-Measure	927	934	overall
I-outcome-Measure	935	943	survival
O	943	944	.

O	945	951	Hazard
O	952	958	ratios
O	959	960	(
O	960	963	HRs
O	963	964	)
O	965	969	were
O	970	977	derived
O	978	982	from
O	983	986	Cox
O	987	993	models
O	993	994	,
O	995	998	and
O	999	1002	all
O	1003	1014	statistical
O	1015	1020	tests
O	1021	1025	were
O	1026	1029	two
O	1029	1030	-
O	1030	1035	sided
O	1035	1036	.

O	1037	1044	Between
O	1045	1049	1993
O	1050	1053	and
O	1054	1058	2000
O	1058	1059	,
B-total-participants	1060	1064	2144
O	1065	1066	(
B-intervention-participants	1066	1070	1063
O	1071	1078	ovarian
O	1079	1087	ablation
O	1088	1090	or
O	1091	1102	suppression
O	1102	1103	,
B-control-participants	1104	1108	1081
O	1109	1111	no
O	1112	1119	ovarian
O	1120	1128	ablation
O	1129	1131	or
O	1132	1143	suppression
O	1143	1144	)
O	1145	1153	patients
O	1154	1158	were
O	1159	1167	randomly
O	1168	1176	assigned
O	1176	1177	.

O	1178	1179	A
O	1180	1185	total
O	1186	1188	of
B-intervention-participants	1189	1192	942
O	1193	1194	(
O	1194	1196	89
O	1196	1197	%
O	1197	1198	)
O	1199	1207	received
O	1208	1215	ovarian
O	1216	1224	ablation
O	1225	1227	or
O	1228	1239	suppression
O	1240	1242	as
O	1243	1252	allocated
O	1252	1253	.

O	1254	1261	Overall
O	1261	1262	,
O	1263	1265	no
O	1266	1274	evidence
O	1275	1277	of
O	1278	1279	a
O	1280	1287	benefit
O	1288	1291	for
O	1292	1299	ovarian
O	1300	1308	ablation
O	1309	1311	or
O	1312	1323	suppression
O	1324	1327	was
O	1328	1336	observed
O	1337	1340	for
B-outcome	1341	1348	relapse
I-outcome	1348	1349	-
I-outcome	1349	1353	free
I-outcome	1354	1362	survival
O	1363	1364	(
O	1364	1371	relapse
O	1372	1374	in
O	1375	1378	the
O	1379	1386	ovarian
O	1387	1395	ablation
O	1395	1396	/
O	1396	1407	suppression
O	1408	1414	versus
O	1415	1417	no
O	1418	1425	ovarian
O	1426	1434	ablation
O	1434	1435	/
O	1435	1446	suppression
O	1447	1452	group
O	1452	1453	,
B-iv-bin-abs	1454	1457	290
O	1458	1464	events
O	1465	1471	versus
B-cv-bin-abs	1472	1475	306
O	1476	1482	events
O	1482	1483	,
O	1484	1486	HR
O	1487	1488	=
O	1489	1490	0
O	1490	1491	.
O	1491	1493	95
O	1493	1494	,
O	1495	1497	95
O	1497	1498	%
O	1499	1509	confidence
O	1510	1518	interval
O	1519	1520	[
O	1520	1522	CI
O	1522	1523	]
O	1524	1525	=
O	1526	1527	0
O	1527	1528	.
O	1528	1530	81
O	1531	1533	to
O	1534	1535	1
O	1535	1536	.
O	1536	1538	12
O	1538	1539	;
O	1540	1541	P
O	1542	1543	=
O	1544	1545	.
O	1545	1547	56
O	1547	1548	)
O	1549	1551	or
B-outcome	1552	1559	overall
I-outcome	1560	1568	survival
O	1569	1570	(
O	1570	1575	death
O	1576	1580	from
O	1581	1584	any
O	1585	1590	cause
O	1591	1593	in
O	1594	1597	the
O	1598	1605	ovarian
O	1606	1614	ablation
O	1615	1617	or
O	1618	1629	suppression
O	1630	1636	versus
O	1637	1639	no
O	1640	1647	ovarian
O	1648	1656	ablation
O	1656	1657	/
O	1657	1668	suppression
O	1669	1674	group
O	1674	1675	,
B-iv-bin-abs	1676	1679	215
O	1680	1686	events
O	1687	1693	versus
B-cv-bin-abs	1694	1697	230
O	1698	1704	events
O	1704	1705	,
O	1706	1708	HR
O	1709	1710	=
O	1711	1712	0
O	1712	1713	.
O	1713	1715	94
O	1715	1716	,
O	1717	1719	95
O	1719	1720	%
O	1721	1723	CI
O	1724	1725	=
O	1726	1727	0
O	1727	1728	.
O	1728	1730	78
O	1731	1733	to
O	1734	1735	1
O	1735	1736	.
O	1736	1738	13
O	1738	1739	;
O	1740	1741	P
O	1742	1743	=
O	1744	1745	.
O	1745	1747	44
O	1747	1748	)
O	1748	1749	,
O	1750	1753	nor
O	1754	1758	were
O	1759	1770	differences
O	1771	1775	seen
O	1776	1781	after
O	1782	1792	adjustment
O	1793	1796	for
O	1797	1800	age
O	1800	1801	,
O	1802	1807	nodal
O	1808	1814	status
O	1814	1815	,
O	1816	1818	or
O	1819	1827	estrogen
O	1828	1836	receptor
O	1837	1838	(
O	1838	1840	ER
O	1840	1841	)
O	1842	1848	status
O	1848	1849	.

O	1850	1857	Overall
O	1857	1858	,
O	1859	1861	no
O	1862	1867	added
O	1868	1874	effect
O	1875	1877	of
O	1878	1885	ovarian
O	1886	1894	ablation
O	1895	1897	or
O	1898	1909	suppression
O	1910	1913	was
O	1914	1918	seen
O	1919	1921	on
B-outcome	1922	1929	relapse
I-outcome	1929	1930	-
I-outcome	1930	1934	free
I-outcome	1935	1943	survival
O	1944	1946	or
B-outcome	1947	1954	overall
I-outcome	1955	1963	survival
O	1964	1966	of
O	1967	1980	premenopausal
O	1981	1986	women
O	1987	1990	who
O	1991	1995	were
O	1996	2003	treated
O	2004	2007	for
O	2008	2013	early
O	2013	2014	-
O	2014	2019	stage
O	2020	2026	breast
O	2027	2033	cancer
O	2033	2034	.

O	2035	2042	However
O	2042	2043	,
O	2044	2047	the
O	2048	2052	role
O	2053	2055	of
O	2056	2063	ovarian
O	2064	2072	ablation
O	2073	2075	or
O	2076	2087	suppression
O	2088	2090	in
O	2091	2096	young
O	2097	2098	(
O	2098	2099	<
O	2099	2101	40
O	2102	2107	years
O	2107	2108	)
O	2109	2114	women
O	2115	2119	with
O	2120	2122	ER
O	2122	2123	-
O	2123	2131	positive
O	2132	2138	tumors
O	2138	2139	,
O	2140	2150	especially
O	2151	2156	those
O	2157	2160	not
O	2161	2170	receiving
O	2171	2183	chemotherapy
O	2183	2184	,
O	2185	2193	requires
O	2194	2201	further
O	2202	2207	study
O	2207	2208	.
